IONS vs NVS
IONS: Ionis Pharmaceuticals is a pioneer in RNA-targeted therapies, transitioning into a commercial-stage biotech with a pipeline focused on neurology and cardiometabolic diseases. NVS: Global pharmaceutical and biotechnology company pioneering disease-modifying treatments across oncology, immunology, neuroscience, and rare genetic diseases.
Side-by-side fundamentals
| Metric | IONS | NVS | Edge |
|---|---|---|---|
| Price as of 2026-07-27 close | $55.96 | $156.11 | |
| Market cap as of 2026-08-03 | $9.3B | $232.1B | |
| P/E as of 2026-08-03 | n/a | 22.53 | |
| PEG as of 2026-08-03 | -0.18 | 3.66 | IONS lower |
| Net margin as of 2026-08-03 | -30.9% | +22.5% | NVS higher |
| Gross margin as of 2026-08-03 | +98.3% | +75.0% | IONS higher |
| Operating margin as of 2026-08-03 | -33.3% | +29.9% | NVS higher |
| ROE as of 2026-08-03 | -58.7% | +29.9% | NVS higher |
| ROA as of 2026-08-03 | -10.1% | +11.1% | NVS higher |
| Debt / equity as of 2026-08-03 | 4.76 | 1.18 | NVS lower |
| Revenue growth (YoY) as of 2026-08-03 | +47.4% | +3.3% | IONS higher |
| Revenue CAGR (3y) SEC XBRL | +17.1% | n/a | |
| Dividend yield as of 2026-08-03 | n/a | +2.9% | |
| Beta as of 2026-08-03 | 0.38 | 1.17 | |
| 1-year return as of 2026-07-27 close | +32.4% | +32.6% | NVS higher |
Fundamentals: market data, as of 2026-08-03. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-27.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.